Ilumetri (Tildrakizumab)

Tildrakizumab is a humanized monoclonal antibody that binds to the p19 subunit of interleukin‑23. By blocking IL‑23 from activating its receptor, the drug interrupts a key inflammatory pathway that drives the formation of psoriatic plaques.

The dosing regimen for Ilumetri is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response. Specific dose amounts and intervals are not disclosed here and should follow the approved prescribing information.

Safety data for tildrakizumab in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To request Ilumetri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Ilumetri belongs to the IL‑23 inhibitor class, similar to drugs like guselkumab and risankizumab. All target the IL‑23 pathway but differ in molecular structure, dosing frequency, and clinical trial outcomes. Choice among them depends on physician assessment of efficacy, safety profile, patient preference, and logistical considerations.

Ilumetri must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours.

Ilumetri is supplied as a solution for subcutaneous injection. A healthcare professional administers the injection into the thigh, abdomen, or upper arm according to the prescribed schedule. Patients should be observed for a short period after injection for any immediate reactions.

Serious risks include severe allergic reactions (anaphylaxis), opportunistic infections such as tuberculosis, exacerbation of inflammatory bowel disease, potential malignancies, and rare cardiovascular events. Patients should report any signs of infection, persistent gastrointestinal symptoms, or unusual cardiac symptoms promptly.

Ilumetri is contraindicated in patients with known hypersensitivity to tildrakizumab or any component of the formulation. It should also be avoided in individuals receiving live vaccines or those with active, uncontrolled infections until the infection is resolved.